European neuromodulation CRO for implantable neurostimulation clinical programmes.

Start from the indication rather than from the centre's reputation. The question is how many patients matching your inclusion criteria that centre implanted in the last twelve months, whether the multidisciplinary team your protocol assumes actually exists there, and who has the capacity to programme and follow up study patients alongside routine care.

Eclevar runs the feasibility questionnaire, the qualification visits and the activation tracking in-house, and reports the competing studies already open at each centre, because in neuromodulation the best sites are usually already committed.

A first-in-human investigation has to establish that implantation and stimulation can be delivered safely in the intended population, and that the device performs as designed. It is characterisation, not confirmation: the endpoints are usually procedural success, device performance, adverse event profile and early tolerability, with clinical effect measured descriptively.

The preclinical package, the risk analysis and the benefit-risk argument have to support it before submission. Eclevar prepares the clinical investigation plan, the investigator brochure input and the competent authority and ethics committee submissions.

Both have to be argued for the specific indication, and both have to be fixed before enrolment. A responder threshold that is well established in one chronic pain population does not transfer automatically to another indication, another outcome instrument or another follow-up horizon, and a threshold adopted by convention rather than by justification is a predictable source of Notified Body questions.

The practical approach is to set out the candidate definitions, their published basis and their effect on sample size, and to have the sponsor and the investigators choose on the record.

In structured fields, not in free text. Amplitude, frequency, pulse width, active contacts, programme identifier and the date and reason for each change should all be queryable, so that the analysis can describe what was actually delivered rather than what was prescribed.

Where the device or programmer can export its own configuration record, that export should be reconciled with the electronic data capture record rather than transcribed by hand.

Sustained clinical benefit, device performance over time and the full reoperation picture: lead migration and fracture, connector and extension issues, infection, battery depletion, recharge burden, revision and explant, each with its date and reason.

The plan follows the MDCG 2020-7 template and the results are reported in a PMCF evaluation report using MDCG 2020-8. The follow-up period should reflect the device's expected service life rather than the convenience of the reporting cycle.

Against an event taxonomy defined before first patient in, and reconciled with the sponsor's vigilance and complaint-handling terminology so that the same event is not coded three different ways in three different systems.

Sites need training against that taxonomy, because reporting conventions differ between centres and inconsistent coding is one of the most common reasons a post-market dataset cannot answer the question asked of it.

When the intended purpose changes. If the new indication takes the device outside the population, the anatomical target or the clinical claim covered by the existing clinical evaluation, the manufacturer generally needs its own clinical data rather than a body of investigator-initiated work it does not control.

Investigator-initiated studies can be valuable, but whether their data can later support a clinical evaluation depends on how sponsorship, data ownership and data capture were structured at the outset. That decision cannot be retrofitted.

By asking whether the change affects the device's intended purpose, its safety or its performance. If it does, it is a significant change and needs its own evaluation, and possibly its own clinical data, before it is deployed to patients.

In a study, the practical requirement is traceability: which algorithm or firmware version each patient was on, when it changed, and whether any endpoint data spans a version boundary. Closed-loop systems make this harder, because part of the therapy itself is in the software.

Often, but only if it is planned that way. Study conduct to ISO 14155:2026 is broadly recognised, and a European dataset can contribute to submissions in other jurisdictions where the population, the endpoints and the comparator are acceptable to the reviewing authority.

What decides it is usually whether the target market's expectations were built into the protocol at the start. Retrofitting a European pivotal study to a different jurisdiction's expectations after database lock rarely works.

A registry suits questions about long-term performance, device survival and real-world use in a population already receiving the therapy, where the clinical benefit is established and the question is durability and safety at scale.

A prospective clinical investigation is required where the benefit itself is the question: a new device, a new indication, a new stimulation strategy, or any claim that needs a controlled comparison. In practice many neurostimulation programmes need both, sequenced so the registry extends the investigation rather than substituting for it.